For the Inventor, By the Inventor

Enter assignee name

Hwaseong-Si, Gyeonggi-Do, South Korea

Hanmi Pharm. Co., Ltd.

Calculating rank

USPTO Granted Patents = 16

EPO Patents = 4

Forward Citations = 0

Loading Chart...

Loading Chart...

64 inventors (with patents filed for the assignee):

Jung Kuk Kim (4 out of 13 patents)

Euh Lim Oh (4 out of 4 patents)

Jong Suk Suk Lee (4 out of 4 patents)

4. Ho Taek Im (3 out of 11 patents)

5. Sang Hyun Lee (3 out of 82 patents)

6. Bo Sik Kim (3 out of 3 patents)

7. Ji Hye Moon (3 out of 5 patents)

8. Jae Hyuk Choi (3 out of 3 patents)

9. Eun Jung Kim (3 out of 3 patents)

10. A Ram Lee (2 out of 6 patents)

11. Joo Young Dong (2 out of 2 patents)

12. Ji Eun Lee (2 out of 2 patents)

13. Hyeon Joo Im (2 out of 2 patents)

14. Nyeong Sang Yoo (2 out of 2 patents)

15. Hyuk Jun Cho (2 out of 2 patents)

16 patents: Sort by Forward Citations

1. 12788800 - Composition comprising glucagon and GLP-1 and GIP receptor dual agonist and therapeutic use of same (2026-11-10),

2. 12780901 - NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF (2026-11-03),

3. 12780892 - LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE (2026-11-03),

4. 12779018 - PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES, COMPRISING TRIPLE AGONIST OR CONJUGATE THEREOF HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1 AND GLP RECEPTORS (2026-11-03),

5. 12766196 - PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS (2026-10-20),

6. 12741011 - LIQUID FORMULATION (2026-09-22),

7. 12734218 - USE OF TRIGONAL AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS IN TREATMENT OF SEQUELAE FOLLOWING RESPIRATORY INFECTIOUS DISEASES (2026-09-15),

8. 12708618 - PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING PROTON PUMP INHIBITOR AND ANTACID, AND METHOD FOR PREPARING SAME (2026-08-18),

9. 12703730 - LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES (2026-08-11),

10. 12678407 - Composite formulation comprising sitagliptin and dapagliflozin and preparation method therefor (2026-07-14),

11. 12667624 - GIP DERIVATIVE, LONG-ACTING CONJUGATE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME (2026-06-30),

12. 12649826 - POLYETHYLENE GLYCOL DERIVATIVE, COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING BIOACTIVE POLYPEPTIDE CONJUGATE BY USING SAME (2026-06-09),

13. 12599675 - NOVEL CONJUGATE OF IMMUNE-STIMULATING IL-2 ANALOG AND PREPARATION METHOD THEREOF (2026-04-14),

14. 12582636 - Pharmaceutical composite formulation comprising proton pump inhibitor and antacid (2026-03-24),

15. 12558431 - NOVEL METHOD OF PREPARING PROTEIN CONJUGATE (2026-02-24),

Company Overview

Hanmi Pharm. Co., Ltd. is a South Korean pharmaceutical company headquartered in Hwaseong-Si, Gyeonggi-Do. The company specializes in the development and manufacturing of innovative pharmaceuticals, focusing on areas such as oncology, diabetes, and cardiovascular diseases. Hanmi is dedicated to advancing drug discovery and enhancing therapeutic options through its robust research and development initiatives, aiming to improve patient outcomes both domestically and internationally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

16 Patents

#90 in HWASEONG-SI, GYEONGGI-DO

#749 in South Korea

#37,952 in the World

Hwaseong-Si, Gyeonggi-Do, South Korea

Hanmi Pharm. Co., Ltd.

Forward Citations = 0

64 inventors:

Jung Kuk Kim (4 out of 13 patents)

Euh Lim Oh (4 out of 4 patents)

Jong Suk Suk Lee (4 out of 4 patents)

4. Ho Taek Im (3 out of 11 patents)

5. Sang Hyun Lee (3 out of 82 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hanmi Pharm. Co., Ltd.. Retrieved from https://idiyas.com/company/hanmi-pharm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…